Skip to main content
CYCLOPHARM LIMITED logo

CYCLOPHARM LIMITED — Investor Relations & Filings

Ticker · CYC ISIN · AU000000CYC5 LEI · 9845008C9R4608FB7007 ASX Manufacturing
Open in API
Filings indexed 777 across all filing types
Latest filing 2021-05-03 AGM Information
Country AU Australia
Listing ASX CYC

About CYCLOPHARM LIMITED

https://www.cyclopharm.com.au

Cyclopharm Limited focuses on the development and commercialization of specialized medical imaging technologies. Its primary product, Technegas, is an ultra-fine dispersion of carbon nano-particles labeled with Technetium-99m, utilized for functional lung ventilation imaging. This technology is used to diagnose Pulmonary Embolism by providing high-resolution images via the inhalation of a radioactive aerosol. Technegas is generated on-site using proprietary equipment and is compatible with SPECT and SPECT/CT imaging. The system is engineered to provide diagnostic clarity even in patients with underlying airway diseases. Beyond its primary diagnostic use, the company investigates applications for its technology in managing chronic obstructive pulmonary disease (COPD), asthma, and lung cancer.

Recent filings

Filing Released Lang Actions
CYC 2021 AGM Presentation 37 pages 2.5MB
AGM Information Classification · 95% confidence The document is titled '2021 Annual General Meeting' and contains content typical of an AGM presentation, including a Chairman's address, Managing Director's address, business highlights, market opportunities, and strategic plans. It includes forward-looking statements, financial highlights, and operational updates but does not contain detailed financial statements or comprehensive annual report data. The length is about 15,000 characters, which is consistent with a presentation rather than a full annual report. There is no indication that this is a full Annual Report (10-K) or an Earnings Release (ER). The content is clearly designed for shareholders at the AGM, consistent with AGM Information filings. Therefore, the document is best classified as AGM Information (AGM-R).
2021-05-03 English
Managing Director's Address to Shareholders 7 pages 173.7KB
Investor Presentation Classification · 95% confidence The document is a detailed presentation by the Managing Director of Cyclopharm Ltd, dated 4 May 2021, discussing financial highlights for 2020, operational and strategic updates, and future growth plans, especially focusing on USFDA approval and market expansion. It includes slides with financial data, business model explanation, clinical trial results, and market opportunity analysis. The content is structured as a presentation with slides and detailed commentary, typical of an investor presentation. It is not a formal annual report, audit report, earnings release, or regulatory filing. The length (15,000 characters) and detailed financial and strategic information support classification as an Investor Presentation rather than a brief announcement or report publication notice.
2021-05-03 English
Ceasing to be a substantial holder from MUFG 3 pages 405.8KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 605 Notice of ceasing to be a substantial holder under the Corporations Act 2001 Section 671B. It details changes in relevant interests of a substantial shareholder, Mitsubishi UFJ Financial Group, Inc., including dates and nature of changes in shareholdings. This type of filing is a notification of changes in significant share ownership levels, which matches the definition of Major Shareholding Notification (MRQ). The document is not a financial report, earnings release, or management report, but a regulatory notice about shareholding changes.
2021-05-03 English
Becoming a substantial holder from MUFG 9 pages 652.1KB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Form 603 Corporations Act 2001 Section 671B' and is a 'Notice of initial substantial holder' for Cyclopharm Limited. It details the substantial shareholding of Mitsubishi UFJ Financial Group, Inc., including voting power, relevant interests, acquisition dates, and associates. This type of filing is a notification of a major shareholding or change in significant ownership levels, which aligns with the definition of 'Major Shareholding Notification' (Code: MRQ). The document is lengthy and detailed, not a brief announcement or a report publication notice, and it does not contain financial statements or management commentary. Therefore, it is classified as a Major Shareholding Notification.
2021-05-03 English
Results of Meeting 2 pages 143.5KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an announcement dated 4 May 2021 from Cyclopharm Limited regarding the results of their Annual General Meeting (AGM). It includes detailed voting results for various resolutions passed at the AGM, such as adoption of remuneration report, re-election of a director, ratification of share placement, approval of loan share plan, amendment of constitution, and approval of non-executive director remuneration. The document references compliance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, which relate to disclosure of voting results. The content is focused on the official results of shareholder votes at the AGM, not the AGM materials or presentations themselves, nor the full annual report or financial statements. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 3226 characters, which is consistent with a voting results announcement rather than a full report or presentation.
2021-05-03 English
CYC Amended Constitution 88 pages 683.6KB
Governance Information Classification · 95% confidence The document is titled 'Amended Constitution' and references adoption by special resolution at the Annual General Meeting (AGM) on 4 May 2021. It contains detailed sections about the company's constitution, including rules on directors, meetings, voting, proxies, and other governance matters. The document is lengthy (15,000 characters) and contains the full text of the amended constitution, not just an announcement or summary. This type of document is a governance-related report detailing the company's internal rules and board structure. It is not an annual report, earnings release, or other financial report. Therefore, the most appropriate classification is Governance Information (CGR).
2021-05-03 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.